The SGLT2 inhibitor, already approved for some high-risk heart failure patients, has now received a much wider approval.
Innovate Healthcare thanks our partners for supporting our newsletters.Sponsorship has no influence on editorial content.Interested in reaching our audiences, contact our team*|LIST:ADDRESSLINE|*You received this email because you signed up for newsletters from Innovate Healthcare.Change your preferences or unsubscribe hereContact Us | Unsubscribe from all | Privacy Policy© Innovate Healthcare, a TriMed Media brand
